• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    5/23/23 9:06:57 AM ET
    $ARDS
    $BACK
    $BIOC
    $BJDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ARDS alert in real time by email

    Gainers

    • CohBar (NASDAQ:CWBR) stock rose 192.9% to $4.54 during Tuesday's pre-market session. The market value of their outstanding shares is at $13.1 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 50.48% to $1.55. The market value of their outstanding shares is at $21.1 million.
    • Biocept (NASDAQ:BIOC) shares increased by 36.43% to $6.74. The market value of their outstanding shares is at $3.9 million.
    • Finch Therapeutics Gr (NASDAQ:FNCH) shares rose 14.39% to $0.33. The market value of their outstanding shares is at $15.7 million.
    • Icosavax (NASDAQ:ICVX) shares moved upwards by 14.23% to $8.99. The market value of their outstanding shares is at $372.4 million.
    • IMAC Hldgs (NASDAQ:BACK) shares moved upwards by 12.83% to $0.16. The company's market cap stands at $5.2 million. As per the press release, Q1 earnings came out 2 days ago.

    Losers

    • Oncorus (NASDAQ:ONCR) shares fell 33.3% to $0.21 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.4 million. As per the press release, Q1 earnings came out yesterday.
    • NantHealth (NASDAQ:NH) shares declined by 23.32% to $1.94. The company's market cap stands at $14.9 million.
    • WAVE Life Sciences (NASDAQ:WVE) stock declined by 15.1% to $3.15. The company's market cap stands at $309.8 million.
    • Integra Lifesciences (NASDAQ:IART) shares fell 14.1% to $43.57. The market value of their outstanding shares is at $3.5 billion.
    • Bluejay Diagnostics (NASDAQ:BJDX) shares decreased by 11.89% to $0.2. The market value of their outstanding shares is at $4.1 million.
    • Aridis Pharmaceuticals (NASDAQ:ARDS) stock fell 11.68% to $0.19. The market value of their outstanding shares is at $7.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARDS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDS
    $BACK
    $BIOC
    $BJDX

    CompanyDatePrice TargetRatingAnalyst
    Wave Life Sciences Ltd.
    $WVE
    2/5/2026$38.00Buy
    BofA Securities
    Wave Life Sciences Ltd.
    $WVE
    12/12/2025$20.00 → $33.00Outperform
    Wedbush
    Wave Life Sciences Ltd.
    $WVE
    12/9/2025$27.00Sector Perform → Outperform
    RBC Capital Mkts
    Wave Life Sciences Ltd.
    $WVE
    10/20/2025$18.00Overweight
    Wells Fargo
    Wave Life Sciences Ltd.
    $WVE
    8/4/2025$19.00Buy
    Canaccord Genuity
    Wave Life Sciences Ltd.
    $WVE
    7/28/2025$24.00Outperform
    Oppenheimer
    Wave Life Sciences Ltd.
    $WVE
    7/16/2025$16.00Buy
    Citigroup
    Wave Life Sciences Ltd.
    $WVE
    6/11/2025$14.00Outperform
    Raymond James
    More analyst ratings

    $ARDS
    $BACK
    $BIOC
    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Wave Life Sciences with a new price target

    BofA Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $38.00

    2/5/26 9:31:24 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush reiterated coverage on Wave Life Sciences with a new price target

    Wedbush reiterated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $33.00 from $20.00 previously

    12/12/25 8:29:31 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Wave Life Sciences from Sector Perform to Outperform and set a new price target of $27.00

    12/9/25 8:38:23 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BACK
    $BIOC
    $BJDX
    SEC Filings

    View All

    SEC Form 424B3 filed by Shuttle Pharmaceuticals Holdings Inc.

    424B3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    3/9/26 8:00:18 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Bluejay Diagnostics Inc.

    10-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/6/26 4:02:15 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/6/26 9:21:49 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ARDS
    $BACK
    $BIOC
    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Francis Chris exercised 33,194 units of Ordinary Shares at a strike of $4.28 and sold $499,593 worth of Ordinary Shares (33,194 units at $15.05) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    2/27/26 9:00:03 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Moran Kyle was granted 45,625 units of Ordinary Shares and sold $48,259 worth of Ordinary Shares (3,588 units at $13.45), increasing direct ownership by 46% to 134,385 units (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    2/11/26 9:03:07 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bolno Paul was granted 165,000 units of Ordinary Shares and sold $140,956 worth of Ordinary Shares (10,480 units at $13.45), increasing direct ownership by 128% to 275,520 units (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    2/11/26 9:02:02 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BACK
    $BIOC
    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gsk Plc bought $27,930,000 worth of Ordinary Shares (1,470,000 units at $19.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    12/15/25 4:32:10 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $6,688 worth of Ordinary Shares (1,000 units at $6.69) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    11/14/25 6:14:02 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Graves Jeffrey A bought $102,150 worth of shares (9,000 units at $11.35), increasing direct ownership by 28% to 41,086 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    11/6/25 4:05:46 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $ARDS
    $BACK
    $BIOC
    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

    ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent progress and its planned strategic trajectory through 2026. Operational and Clinical ProgressBluejay continues to advance its Symphony™ platform, including the Company's lead product candidate for the rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care decision making. The Company confirmed that its SYMON™ II clinical study is progressing as planned, with on

    3/6/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

    Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced acceptance of a late-breaking oral presentation of data from its ongoing RestorAATion-2 clinical trial of WVE-006, its investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic

    3/5/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass Planning underway to initiate Phase 2a multidose portion of WVE-007 INLIGHT clinical trial for obesity in individuals with higher BMI and comorbidities in 1H 2026, as well as additional trials of WVE-007 as an incretin add-on and as post-incretin maintenance in 2026 Advancing regulatory engagement on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing) for AATD with feedback anticipated mid-2026; RestorAATion-2 clinical trial fully enrolled through 60

    2/26/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BACK
    $BIOC
    $BJDX
    Leadership Updates

    Live Leadership Updates

    View All

    Integra LifeSciences Announces Key Executive Leadership Appointments

    PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company. The company also announced the appointments of Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer. The creation of the chief technology officer (CTO) position underscores Integra's commitment to build

    2/17/26 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Shuttle Pharmaceuticals Acquires AI Health Platform

    Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay

    11/21/25 9:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer

    PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world's largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providi

    9/22/25 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $ARDS
    $BACK
    $BIOC
    $BJDX
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass Planning underway to initiate Phase 2a multidose portion of WVE-007 INLIGHT clinical trial for obesity in individuals with higher BMI and comorbidities in 1H 2026, as well as additional trials of WVE-007 as an incretin add-on and as post-incretin maintenance in 2026 Advancing regulatory engagement on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing) for AATD with feedback anticipated mid-2026; RestorAATion-2 clinical trial fully enrolled through 60

    2/26/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance

    PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) --  Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.Adjusted earnings per diluted share were $0.83, compared to $0.97 in the fourth quarter of 2024. Full-Year 2025 Reported revenues were $1,635.2 million, representing an increase of 1.5% on a reported basis and

    2/26/26 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

    CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company's fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the

    2/19/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BACK
    $BIOC
    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc.

    SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

    11/14/24 4:46:40 PM ET
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

    SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 3:54:54 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care